Company Profiles

driven by the PitchBook Platform

Carmot Therapeutics

Description

Developer of drugs for the treatment of metabolic diseases, cancer and inflammation. The company offers a proprietary technology platform, Chemotype Evolution, that enables the identification of novel drugs. Chemotype Evolution is a disruptive technology that creates drugs that are difficult to identify by standard technologies.

2010

Founded

PRIVATE

Status

11-50

Employees

Grant

Latest Deal Type

$2.05M

Total Amount Raised

5

Investors

Description

Developer of drugs for the treatment of metabolic diseases, cancer and inflammation. The company offers a proprietary technology platform, Chemotype Evolution, that enables the identification of novel drugs. Chemotype Evolution is a disruptive technology that creates drugs that are difficult to identify by standard technologies.

Website:

www.carmot.us

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Other Pharmaceuticals and Biotechnology

Primary Office

409 Illinois Street San Francisco, CA 94158United States
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Carmot Therapeutics's full profile, request a free trial.

    Carmot Therapeutics Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Carmot Therapeutics Investors (5)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    Leader VenturesLender/Debt ProviderMinority000 0000000 0000
    Michael J. Fox FoundationOther000 0000000 0000
    National Cancer InstituteGovernment000 0000000 0000
    National Science FoundationGovernment000 0000000 0000
    The Column GroupVenture CapitalMinority000 0000000 0000
    Leader Ventures Lender/Debt Provider
    Michael J. Fox Foundation Other
    National Cancer Institute Government
    National Science Foundation Government
    The Column Group Venture Capital

    Carmot Therapeutics Executive Team (3)

    NameTitleBoard
    Seat
    Contact
    Info
    Stig Hansen Ph.DCo-Founder, Board Member & Chief Executive Officer
    Daniel Erlanson Ph.DCo-Founder, Vice President of Chemistry & Board Member
    Roman Dvorak Ph.DVice President of Clinical Development
    Stig Hansen Ph.D Co-Founder, Board Member & Chief Executive Officer
    Daniel Erlanson Ph.D Co-Founder, Vice President of Chemistry & Board Member
    Roman Dvorak Ph.D Vice President of Clinical Development

    Carmot Therapeutics Board Members (4)

    NameRepresentingRoleSinceContact
    Info
    Aetna Trombley Ph.DSelfBoard Member000 0000
    Daniel Erlanson Ph.DCarmot TherapeuticsCo-Founder, Vice President of Chemistry & Board Member000 0000
    Laurence Lasky Ph.DSelfBoard Member000 0000
    Timothy Kutzkey Ph.DThe Column GroupManaging Partner000 0000
    Aetna Trombley Ph.D Board Member Self
    Daniel Erlanson Ph.D Co-Founder, Vice President of Chemistry & Board Member Carmot Therapeutics
    Laurence Lasky Ph.D Board Member Self
    Timothy Kutzkey Ph.D Managing Partner The Column Group
    Request full access to PitchBook